ramipril vs telmisartan
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of ramipril and telmisartan. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
moderate Known Drug Interaction
In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see Dual Blockade of the Renin-Angiotensin-Aldosterone System ( 5.7 ) ].
Altace
Micardis
Ramipril is a medicine that lowers blood pressure. It can also help people with heart failure after a heart attack.
Telmisartan (Micardis) is a medicine that lowers blood pressure. It belongs to a class of drugs called angiotensin II receptor blockers (ARBs).
Ramipril is used to treat high blood pressure. It can be used alone or with other blood pressure medicines. It is also used in patients who have signs of heart failure after a heart attack. Ramipril can lower the risk of death and hospitalization in these patients.
Telmisartan is used to treat high blood pressure. Lowering blood pressure reduces the risk of strokes and heart attacks. It can also lower cardiovascular risk if you cannot take ACE inhibitors. Controlling high blood pressure is important for overall heart health.
Ramipril belongs to a class of drugs called ACE inhibitors. It works by blocking a substance in your body that tightens blood vessels. This helps your blood vessels relax and lowers your blood pressure.
Telmisartan blocks a substance in your body that tightens blood vessels. This helps blood vessels relax and widens them. As a result, blood pressure is lowered.
- • Headache
- • Dizziness
- • Fatigue
- • Cough
- • Back pain
- • Sinus infection
- • Diarrhea
- • Upper respiratory tract infection
- • Sore throat
- Dyspnoea 8,083
- Fatigue 7,877
- Nausea 7,339
- Diarrhoea 6,913
- Dizziness 6,526
- Nausea 2,059
- Fatigue 2,001
- Diarrhoea 1,794
- Dyspnoea 1,785
- Headache 1,715
This drug can cause serious harm or death to an unborn baby. If you are pregnant or plan to become pregnant, tell your doctor right away. Stop taking ramipril as soon as you know you are pregnant.
If you are pregnant or plan to become pregnant, stop taking this medicine right away. Telmisartan can harm or cause death to your unborn baby.
Do not take ramipril if you are pregnant. It can harm your unborn baby. It is not recommended to use ramipril if you are breastfeeding.
Telmisartan can cause harm to your unborn baby, especially during the second and third trimesters. Do not breastfeed while taking telmisartan.
Also Compare, Nearby Drugs
Compare ramipril with
Compare telmisartan with
How to Read This ramipril vs telmisartan Comparison
ramipril is classified in the ACE Inhibitor drug class, while telmisartan sits within the Angiotensin II Receptor Blocker (ARB) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, ramipril has 36,738 submissions while telmisartan has 9,354. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known moderate interaction flagged in FDA labeling, attributed to taking these two types of blood pressure medicines together can put too much stress on your kidneys and increase the risk of kidney damage.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for ramipril or telmisartan.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.